Fortress Biotech, Inc.: Form 10-Q for the period ended Mar 31, 2020
Filed with the SEC on May 11, 2020 and accepted by EDGAR at May 11, 2020, 16:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-01 to 2020-03-31 | $12.9m | us-gaap:Revenues |
| Cost of revenue | 3 months2020-01-01 to 2020-03-31 | $3.8m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2020-01-01 to 2020-03-31 | $15.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-01-01 to 2020-03-31 | −$21.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2020-01-01 to 2020-03-31 | −$12.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-01-01 to 2020-03-31 | −$0.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-01-01 to 2020-03-31 | −$0.19 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-01-01 to 2020-03-31 | 63,496,256 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2020-01-01 to 2020-03-31 | −$21.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-01-01 to 2020-03-31 | $526.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-03-31 | $135.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-31 | $158.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-31 | $228.8m | us-gaap:Assets |
| Current liabilities | At period end2020-03-31 | $51.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-03-31 | $153.5m | us-gaap:Liabilities |
| Long-term debt | At period end2020-03-31 | $89.7m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2020-03-31 | $37.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-20-059592. Last ingested by Listed: Oct 29, 2026, 17:38 ET. Listed shows no prices and gives no investment advice.